Literature DB >> 24969692

Crucial and novel cancer drivers in a mouse model of triple-negative breast cancer.

Jacob P S Johnson1, Prashant Kumar2, Miroslav Koulnis3, Milan Patel4, Karl Simin1.   

Abstract

BACKGROUND: We previously developed a mouse model of breast cancer that mimics human triple-negative breast cancer (TNBC) by inactivating the Retinoblastoma (Rb), Transformation related protein 53 (p53), and Breast cancer 1 (Brca1) pathways in the mammary gland. Despite inactivation of all three tumor suppressors throughout the epithelium, low tumor multiplicity indicated that malignant carcinoma progression requires additional oncogenic stimuli.
MATERIALS AND METHODS: In order to identify collaborating genetic events, we performed integrated analysis of 18 tumors (eight tumors with inactivation of pRbf/Brca1/p53 and ten tumors with inactivation of pRbf/p53) using comparative genomic hybridization and global gene expression. We then conducted flow cytometric analysis, immunostaining, tumorsphere, and cell viability assays.
RESULTS: Copy number aberrations were correlated with the transcript levels of 7.55% of genes spanned by the altered genomic regions. Recurrent genomic losses spanning large regions of chromosomes 4 and 10 included several cell death genes. Among the amplified genes were well-known drivers of tumorigenesis including Wingless-related MMTV integration site 2 (Wnt2), as well as potentially novel driver mutations including the Late cornified envelope (LCE) gene family. These tumors have a stem/luminal progenitor phenotype and active β-catenin signaling. Tumorsphere formation and cell survival are suppressed by Wnt pathway inhibitors.
CONCLUSION: Our novel mouse model mimics human TNBC and provides a platform to triage the pathways that underlie malignant tumor progression. Copyright
© 2014, International Institute of Anticancer Research (Dr. John G. Delinasios), All rights reserved.

Entities:  

Keywords:  Arid; Breast cancer; CGH; LCE; Mapk; Myc; Wnt; integrative analysis; mouse model; oncogene; triple-negative; tumor suppressor

Mesh:

Year:  2014        PMID: 24969692

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  7 in total

Review 1.  Potential relevance of microRNAs in inter-species epigenetic communication, and implications for disease pathogenesis.

Authors:  Pál Perge; Zoltán Nagy; Ábel Decmann; Ivan Igaz; Peter Igaz
Journal:  RNA Biol       Date:  2016-10-28       Impact factor: 4.652

2.  Cross-kingdom inhibition of breast cancer growth by plant miR159.

Authors:  Andrew R Chin; Miranda Y Fong; George Somlo; Jun Wu; Piotr Swiderski; Xiwei Wu; Shizhen Emily Wang
Journal:  Cell Res       Date:  2016-01-22       Impact factor: 25.617

3.  Data-Driven Discovery of Extravasation Pathway in Circulating Tumor Cells.

Authors:  S Yadavalli; S Jayaram; S S Manda; A K Madugundu; D S Nayakanti; T Z Tan; R Bhat; A Rangarajan; A Chatterjee; H Gowda; J P Thiery; P Kumar
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379

Review 4.  Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype.

Authors:  Fangyuan Shao; Heng Sun; Chu-Xia Deng
Journal:  Oncotarget       Date:  2017-08-16

Review 5.  Targeting the Hippo Pathway for Breast Cancer Therapy.

Authors:  Liqing Wu; Xiaolong Yang
Journal:  Cancers (Basel)       Date:  2018-11-05       Impact factor: 6.639

6.  Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy.

Authors:  Chunai Gong; Jing Tian; Zhuo Wang; Yuan Gao; Xin Wu; Xueying Ding; Lei Qiang; Guorui Li; Zhimin Han; Yongfang Yuan; Shen Gao
Journal:  J Nanobiotechnology       Date:  2019-09-03       Impact factor: 10.435

7.  Mutant PIK3CA Induces EMT in a Cell Type Specific Manner.

Authors:  Divya Bhagirath; Xiangshan Zhao; Sameer Mirza; William W West; Hamid Band; Vimla Band
Journal:  PLoS One       Date:  2016-12-12       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.